World Conference on Pharma Industry and Medical Devices December 05-06, 2022 Zurich, Switzerland

Track 1: Pharma Industry

Pharma industry combines a broad range of scientific disciplines that are involved with the design, action, delivery, disposition and use of drugs. This field draws on numerous regions of the essential and connected sciences, for example, science, science the study of disease transmission, measurements, chemo metrics, arithmetic, material science and compound building and applies their standards to the investigation of medications.

• Pharma formulations                                
• Bio pharmaceutics
• Pre formulation studies
• Pharma biotechnology
• Routes of drug delivery
• Pharma material

Track 2: Technology in Pharma Sciences

Healthcare information technology is the area of information technology system involving the design, development, creation, use and maintenance of information system approaches to improve public health, medical care, lower cost, increase efficiency, reduce errors and improve patient satisfaction for the  healthcare industry. These include uses of data analytics, artificial intelligence, cognitive computing and many others to effectively manage patient health management programs, development of new therapies and drugs, efficient aggregation and analysis of patient information.

Track  3: Novel Drug Delivery Systems, Biomarkers & Drug Targets

The main advantage of Novel Drug Delivery System is providing the drug to the target site in a controlled manner for enhanced efficacy with less side effects. It follows two approaches one is spatial drug delivery which involves targeting a drug to a particular organ or tissue and another one is temporal drug delivery. In this the rate of the drug delivery to the target tissue is controlled by various techniques.

Track 4: Bioequivalence and Bio availability

Bioavailability can be referred to as the rate and extent to which active ingredient or active element of the drug product is absorbed and becomes available at the site of action. The extent and rate of drug absorption are usually measured by the area under the blood or plasma concentration-time curve  (AUC) and the maximum concentration (C max), respectively. 

Bioequivalence: When two drug products or two formulations of the same drug provide the same therapeutic effect, they are said to be bioequivalent, or, that they are therapeutically equivalent. It means, their rates and extent of absorptions do not reflect a significant difference at the site of action.

Track  5: Clinical Pharmacy and Pharmacy Practices

Clinical pharmacy and pharmacy practice play important roles in clinical trials and clinical research. In recent years pharmacist role in clinical research and patient care has improved significantly and they play active role in designing and modifying drug therapies. This session focuses on the recent advancements in clinical research and pharmacy practice.

Track 6: Pharmacogenomics 

Pharmacogenomics and Pharmacogenomics can assist the physicians achieve the target of personalized medicine. Personalized medicine will come to mean not just the right drug for the right individual, but the right drug for the specific infection disease influence a specific individual. It is a major challenge in current clinical practice, drug development, and drug regulation. 

Track 7: Pharmacology and Toxicology

The Pharmaceutical Industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured based on findings from the study of life sciences. Clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat. 

Toxicology is the scientific study of adverse effects that occur in living organisms due to chemicals. It involves observing and reporting symptoms, mechanisms, detection and treatments of toxic substances, in particular relation to the poisoning of humans. 

Session 8: Pharmaceutical Manufacturing 

 Pharmaceutical Manufacturing is the procedure of Pharmaceutical Drugs by pharmaceutical manufacturing companies. It is under constant pressure to fast-track innovation and increase the speed at which they introduce successful drugs to market. The days of big pharmaceutical companies owning many manufacturing plants are slowly ending, and every company, no matter what size, is looking for ways to lessen costs to survive in an increasingly tough and unpredictable economic climate.

Pharma economics is analysed as a part of decision processes at several stages of drug development and drug marketing. Greater challenges in decision-making coupled with improvements in the techniques of pharma economic research point to a greater role for pharma economics into the new millennium. This in turn will have consequences for companies in the pharmaceutical industry.

Track 9: Digital Pharma and Marketing

Digital marketing will be the next frontier for pharmaceutical companies as many of them are scaling up their consumer businesses and introducing an array of consumer brands. Traditionally, marketing innovation in the pharmaceutical industry has been stunted by heavy regulatory restrictions. Historically, pharmaceutical companies have had little to no interaction with their end-users-patients-since they depended entirely on their health care providers for medical knowledge and advice. The $17 billion pharmaceutical industry is currently undergoing a digital wave.

Session 10: The future of Pharma R&D

R&D has traditionally been and will continue to be (probably even more) crucial for the growth and future success of research-based pharma companies. The pharmaceutical industry has now entered a period of significant uncertainty and transition characterized by higher R&D costs, depleted pipelines and financial restriction to perform innovative research. The global credit crunch exacerbates all this with more and more layoffs and research budget cuts, but major crisis can sometimes produce major opportunities. 

Track 11: MedTech

A medtech is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

Importance & Scope:

MedTech-2022 is a best platform to present and discuss current aspect in drug research and development. Pharma chemistry is the study of interaction of chemical with living systems. It is important to discuss the pharmacological basis of therapeutics in order to maximize the benefits and minimize the risks of drugs to recipients. Hence it will be the best platform for scientists, researchers, PhD Scholars, Graduates and Post Graduates involved with drug development.

The global MedTech market size was USD 432.23 billion in 2020. The global impact has been unprecedented and staggering, with medtech witnessing a negative impact on the adoption rate across all regions amid the pandemic. Based on our analysis, the global market exhibited a decline of 3.7% in 2020 as compared to the average year –on-year growth during 2017-2019. The market is projected to grow from USD 455.34 billion in 2021 to USD 657.98 billion in 2028 at a CAGR of 5.4% in the 2021 -2028 period. The sudden rise in CACR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.

The growing prevalence of chronic diseases, and the increasing emphasis of healthcare agencies towards early diagnosis and treatment, is leading to an increasing number of patients undergoing diagnostic and surgical procedures. According to the American Hospital Association (AHA), there were an estimated 36.2 million inpatient admissions in the U.S. in 2019. The rise in the number of inpatient admissions and the increasing number of surgical and diagnostic procedures is fueling the demand for medtech, including capital equipment and consumables in developed and emerging countries.